SS-31 and MOTS-c: Therapeutic Agents Targeting Mitochondrial Health and Aging

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

The Role of Mitochondria in Cellular Function

Mitochondria are membrane-bound organelles that serve as the primary source of cellular energy. They generate adenosine triphosphate (ATP), which fuels biochemical processes. Structurally, mitochondria possess both an outer and inner membrane, each performing specialized functions. These organelles continuously undergo fission and fusion, forming dynamic networks rather than existing as isolated units.

The number of mitochondria varies according to tissue type and energy demand. For instance, red blood cells lack mitochondria, while liver cells may contain thousands. In cardiomyocytes, mitochondria can occupy nearly half of the cytoplasmic volume, reflecting the high metabolic requirements of the heart.

Age-Related Mitochondrial Decline

As individuals age, mitochondrial integrity and efficiency decline due to genetic mutations and oxidative damage from reactive oxygen species (ROS). This leads to:

• Reduced oxidative phosphorylation
• Diminished ATP output
• Impaired antioxidant capacity
• Increased mitochondrial ROS production
• Dysregulation of mitochondrial dynamics and autophagy

With advancing age, these impairments promote apoptosis and contribute to tissue degeneration. Interventions such as caloric restriction, physical exercise, and pharmacological agents have shown promise in delaying these degenerative changes.

Clinical Relevance of Mitochondrial Dysfunction

Mitochondrial disease manifests across multiple organ systems and may result in fatigue, metabolic disorders (such as diabetes mellitus), cardiovascular complications, neuromuscular impairments, seizures, and cognitive decline. Secondary mitochondrial dysfunction has also been implicated in major age-related conditions, including Alzheimer’s disease, muscular dystrophy, amyotrophic lateral sclerosis, and cancer.

SS-31 (Elamipretide, MTP-131, Bendavia)

Mechanism of Action

SS-31 is a mitochondria-targeted peptide that localizes to the inner mitochondrial membrane. It binds to cardiolipin, a phospholipid crucial for maintaining the structure and function of the electron transport chain. Through this interaction, SS-31 stabilizes mitochondrial membranes, enhances electron transport, reduces ROS generation, and prevents cytochrome c release. Additionally, it inhibits opening of the mitochondrial permeability transition pore, thereby reducing cell death under stress conditions.

Research Highlights

1. Neuroinflammation and Cognitive Protection
   In a murine model, SS-31 improved mitochondrial function and reduced oxidative stress caused by lipopolysaccharide (LPS). Treatment mitigated synaptic loss, apoptosis, and memory impairment, partly through the restoration of brain-derived neurotrophic factor (BDNF) signaling.
2. Vascular and Cognitive Benefits in Aging
   In aged mice, SS-31 improved neurovascular coupling, enhanced nitric oxide–mediated vascular responses, and preserved cognitive performance. These outcomes were associated with reduced oxidative damage and improved endothelial mitochondrial respiration, suggesting a role in preventing vascular cognitive impairment.

MOTS-c

Biological Function

MOTS-c is a mitochondrial-derived peptide encoded within the 12S rRNA region of mitochondrial DNA. It regulates metabolic balance by activating AMP-activated protein kinase (AMPK), which enhances mitochondrial biogenesis and energy metabolism. This occurs via modulation of the methionine–folate cycle and purine biosynthesis pathways.

Link to Cellular Senescence

MOTS-c has demonstrated the ability to counteract cellular senescence. Senescent cells, which cease replication but secrete pro-inflammatory signals, contribute to tissue dysfunction and aging. By stimulating AMPK, MOTS-c alleviates some detrimental effects of senescent cells, thereby supporting healthier aging.

Research Findings

Experimental data indicate that MOTS-c improves insulin sensitivity, reduces diet-induced obesity, and protects against age-related metabolic decline. Its primary activity appears within skeletal muscle, where it enhances energy utilization and maintains metabolic homeostasis.

Overall Perspective

Mitochondrial decline is a hallmark of aging, characterized by reduced energy production, increased oxidative stress, and impaired quality control mechanisms. This dysfunction underlies a wide range of chronic diseases and contributes to systemic inflammation, often described as “inflammaging.”

Targeted interventions such as SS-31 and MOTS-c represent promising therapeutic strategies. By restoring mitochondrial efficiency, reducing oxidative stress, and modulating cellular pathways, these agents may help delay age-related decline and improve healthspan.

REFERENCES

1. Payne, B. A., & Chinnery, P. F. (2015). Mitochondrial dysfunction in aging: Much progress but many unresolved questions. Biochimica et biophysica acta, 1847(11), 1347–1353. https://doi.org/10.1016/j.bbabio.2015.05.022
2. The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance
3. Mitochondrial Aging and Age-Related Dysfunction of Mitochondria
4. Kamogashira, T., Hayashi, K., Fujimoto, C., Iwasaki, S., & Yamasoba, T. (2017). Functionally and morphologically damaged mitochondria observed in auditory cells under senescence-inducing stress. NPJ aging and mechanisms of disease, 3, 2. https://doi.org/10.1038/s41514-017-0002-2

Product available for research use only: